Skip to content
drillr.ai
Sign up

603669.SH

Lionco Pharmaceutical Group Co., Ltd.

SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

CNY 5.85
−7.58%
Ask drillr

  • Oct 23, 2026, 08:17 UTC

    Lingkang Pharmaceutical reported first-nine-month 2026 revenue of 360 million yuan, up 27.79% year over year, net profit attributable to shareholders of 31.8266 million yuan, and adjusted net profit of 23.6059 million yuan.

    Source:

  • Oct 23, 2026, 08:17 UTC

    Lingkang Pharmaceutical reported third-quarter 2026 revenue of 103 million yuan, down 6.83% year over year, and net profit attributable to shareholders of 10.7139 million yuan, up 770.67%.

    Source:

  • Sep 29, 2026, 07:32 UTC

    Hainan Lingkang Pharmaceutical, a wholly owned subsidiary of Lingkang Pharmaceutical, received a drug registration certificate from the National Medical Products Administration for isavuconazole sulfate for injection (0.2g), indicated for adult invasive aspergillosis and invasive mucormycosis.

    Source:

  • Aug 14, 2026, 15:57 UTC

    Lingkang Pharmaceutical reported its 2026 half-year results, with revenue of 257 million yuan, up 50.03% year-on-year, and net profit attributable to shareholders of 21.11 million yuan, turning from a loss to a profit.

    Source:

  • Aug 14, 2026, 10:54 UTC

    Lingang Pharmaceutical announced its 2026 first-half results, reporting a net profit of 21.1127 million yuan, turning around from a loss in the prior year.

    Source:

  • Aug 12, 2026, 07:38 UTC

    Lingang Pharmaceutical's subsidiary Lingang Pharma's product Huperzine A for injection (brand Ruilisu) was selected in a provincial alliance centralized procurement led by Henan Province, with a 2-year procurement cycle.

    Source: